Literature DB >> 21086075

Combination lipid therapy in type 2 diabetes.

Michael Clearfield1.   

Abstract

Entities:  

Year:  2011        PMID： 21086075     DOI： 10.1007/s11883-010-0139-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  7 in total

1.  Combination lipid therapy in type 2 diabetes.

Authors:  Frank M Sacks; Vincent J Carey; Jean-Charles Fruchart
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

2.  Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.

Authors:  Peter H Jones; Michael H Davidson
Journal:  Am J Cardiol       Date:  2005-01-01       Impact factor: 2.778

3.  Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.

Authors:  V Manninen; L Tenkanen; P Koskinen; J K Huttunen; M Mänttäri; O P Heinonen; M H Frick
Journal:  Circulation       Date:  1992-01       Impact factor: 29.690

4.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

5.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Authors:  H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

6.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

Authors: 
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

7.  Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Authors:  Russell Scott; Richard O'Brien; Greg Fulcher; Chris Pardy; Michael D'Emden; Dana Tse; Marja-Riitta Taskinen; Christian Ehnholm; Anthony Keech
Journal:  Diabetes Care       Date:  2008-11-04       Impact factor: 19.112
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.